News

Keep up to date with us.

Sonic Incytes to Present Data at EASL International Liver Congress™️ 2023

Velacur™️ ACE Outperforms FibroScan®️ CAP for Liver Fat Quantification

We are excited to announce that clinical data from Sonic Incytes’ multi-center study will be presented at the prestigious European Association for the Study of the Liver (EASL) International Liver Congress™ 2023 in Vienna, Austria. The poster presentation highlights the comparison between point-of-care liver quantification tools, demonstrating Velacur as a superior method for measuring liver fat in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as compared to FibroScan, when using MRI-PDFF as a reference point.

Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) has become the gold standard in non-invasive liver fat assessment, but its use is limited because of cost and accessibility issues. The aim of the study was to compare two point-of-care methods to MRI PDFF, Velacur’s Attenuation Coefficient Estimation (ACE) and FibroScan’s Controlled Attenuation Parameter (CAP) in patients with clinically proven NAFLD or NASH. Both these methods use ultrasound attenuation as a surrogate measure of liver fat as measured by MRI-PDFF.

Velacur’s ACE measurement had a stronger correlation with MRI-PDFF in all patients and in every body mass index (BMI) category, when compared to FibroScan’s CAP measurement. Given the mechanism of action for many of the drugs in development for NASH target fat, Velacur is an ideal tool to monitor therapeutic efficacy given its affordability, accessibility, and accuracy in quantifying steatosis, particularly in obese patients.

The poster, titled “Velacur ACE Outperforms CAP for Liver Fat Quantification using MRI-PDFF as Gold Standard” will be presented on Saturday, June 24th.

Poster Number: SAT-432

Authors:

  • R. Loomba, University of California, San Diego
  • A. Ramji, University of British Columbia
  • T. Hassanein, Southern California Research Center
  • C. Schneider, Sonic Incytes Medical Corporation
  • E. Yoshida, University of British Columbia
  • M. Curry, Beth Israel Deaconess Medical Center
  • E Pang, Vancouver Coastal Health Research Institute

About Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD), including non-alcoholic hepatic steatosis (NASH), is a global health crisis affecting 30% of the population and is often associated with obesity, diabetes and metabolic syndrome. Approximately 20% of those with NAFLD progress to non-alcoholic steatohepatitis (NASH), which can cause inflammation, liver cell damage, fibrosis and ultimately cirrhosis. If detected early, the condition can be reversed.

About Velacur

Velacur is the first liver assessment tool with 3D S-WAVE technology to provide real-time assessments of liver tissue stiffness and attenuation. Velacur combines elements of magnetic resonance elastography, shear wave ultrasound, and liver visualization to deliver accurate measurements in a point-of-care setting. Low cost and portable, Velacur can be administered by a trained medical assistant during a typical office visit.

About Sonic Incytes
Sonic Incytes is dedicated to developing accessible solutions that provide health insights to enhance patient care. In response to the growing prevalence of chronic liver disease, Sonic Incytes is determined to establish liver health as a new vital sign. Their novel point-of-care ultrasound-based imaging solution, Velacur, is redefining the standard of care in quantifying liver tissue stiffness and attenuation to aid in the clinical management of patients with chronic liver disease.

Sync up

with Sonic

Be in-the-know on all our latest news!

Subscribe to our e-newsletter.